Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I’m sure American SH will be jumping for joy with the increase to 1.60 USD just another 6 fold increase to go from here to get their money back.
I think the EUDA SP has performed almost as badly as this one, well not quite as bad but certainly in the hall of fame of lost causes
Apparently up 30 % in the last 5 days according to Yahoo Finance.
Clearly something is happening soon.
🥱🥱🥱🥱oh feel so tired don’t know how many more years to wait 😴😴😴😴
Mean time , there is no news about lates changes in company. Could that be another blackmailing share holders ? Possibly.
Nom,
I'd imagine it was a "Hobson's Choice".
🙃
"Ambrose Healthcare are in discussions to close their first round of investment in "early spring"."
Does that mean that Suzy chose to do a 'commercial' deal with a partner who had no money yet again; some would have hoped she had not found the experience with the TRX rewarding enough to repeat?
"Subject to the exercise of the Option by Ambrose Healthcare, the agreement details clinical and commercial milestone payments to be made to ValiSeek totalling a value of up to £16 million plus royalties."
RNS - https://tinyurl.com/299zmsb4
V401, ignore me bad. Mondays. Cheers pal.
You have lost me Bad. What does that mean for Valirx? Kind Regards
Well hoosy,
Ambrose Healthcare are in discussions to close their first round of investment in "early spring".
https://www.linkedin.com/posts/ambrose-healthcare_startupshowcase-pitchevent-healthcare-activity-7174412483011444737-sGA5?utm_source=share&utm_medium=member_android
Spring officially starts on Wednesday...🤪
This is so boring now. End of the month's update will be interesting. Maybe Suzy coming off twitter is the start of her walking before being pushed? Who knows. What a sh't show this share has become. Well done Suzy.
😴🥱💩
Strong rise on Friday. More like buys than sells.
Big investor reducing its position in EUDA, not sure I like it:
————
Hudson Bay Capital Management LP Sells 760,500 Shares of EUDA Health Holdings Limited (NASDAQ:EUDA)
Very surprised that these two £60k buys haven't provoked any responses, either on this board or to the SP. Someone suggested they might just be rollovers, whatever that means.
Complaining about ads while advertising 🤔
796
Price: 3.675
Strong Buy
Significant upsideToday 17:40
It shows the value on offer and potential upside from here when 201 completes. We were stable in 40s with a peak at 65p with LOI and no CLX, Imogen or lab so at 30p a steal and still very likely to complete shortly.
I have a low average anyway so it matters now. I was massively in profit now but it matters now.
Expecting merger to complete this month and a strong recovery.
ReplyRecommendReport Post
It shows the value on offer and potential upside from here when 201 completes. We were stable in 40s with a peak at 65p with LOI and no CLX, Imogen or lab so at 3p a steal and still very likely to complete shortly.
I have a low average anyway so it matters now. I was massively in profit now but it matters now.
Expecting merger to complete this month and a strong recovery.
PM2022
Posts: 2,795
Price: 3.675
Strong Buy
RE: A bust approachToday 17:03
Again you fail to understand the absolute basics and if people were really honest they would know it
ERM. “30p+++toped up again cheap as chips with no down side”
Be honest with yourself PM you are totally clueless… but fair play you keep me amused with your ridiculous posts week in week out. If you had taken Pork’s advice on the placing instead of disgustingly verbally abusing him you would not be in the desperate state your in now….. up to you neck in and clutching at straws.
Again you fail to understand the absolute basics and if people were really honest they would know it.
So you talk about 9 evaluations. If these were outsourced to external labs that would be a very significant extra cost compared to bringing them into your own lab times that by 9. Also bringing them internally gives control of timings and allows further testing using some of the agreed collaborations they have therefore giving better chances of positive outcomes.
I don't know as much about Imogen and the biobank business but I doubt you do either but what they are saying is that it will help generate significant revenue soon. The lab alone is not likely to do that. If that is the case then all we can do is wait and see. Valirx is not a lab business just are looking for side revenue and mainly to help progress the evaluation projects.
The only part I would agree with is that they should not spend more on other assets for a long while. Keep spending down until a real deal so that actually means bringing in 3 quality projects a year until they strike a deal. What you don't want is to be funding numerous preclinical projects at the same time at a low share price or without a deal with revenue because then the costs will blow.
@PM2022
As I posted last week, I suspect you are either married to Suzy or a connected party in some way as nobody in their right mind would back keeping both Suzy CEO and Jerry FD on the BOD - No way.
As for your counter to my point about adding new additions, I don’t agree and further I think many many investors would share my view:-
They are currently wasting £600k adding to the biobank and a further chunk of change to promote the lab.
Meanwhile a new drug addition evolution was costing £75k to £100k per go. Hence I would rather 7-8 new drug additions to be developed rather than waste that cash on that biobank that Imogen had already spent millions on and still couldn’t make it viable.
I reckon if you asked anyone here where do you want your investment spent labs or evolutions, they would pick drug dev all day long as that is what many originally came here to invest in, to try and make a difference. All sense of perspective has been lost by the BOD if you ask me - that’s how I see it.
And finally, investors didn’t tip cash up for this to pay bonuses and perks either. It’s totally shameful the events here frankly
The resurrected post to which PM objects is only a couple of weeks older than the 2nd November 2021 RNS which said of the 'deal' with Theoremrx 'The first payments are expected by the end of 2021.'
So the LOI and TheoremRx dealings are by your definition irrelevant. I have to agree with you on that basis.
You cannot counter my point instead of turning to a post many years back. Weak..
Share price is dictated by market perception of which 0% on this board really understand the strategy fully therefore a false price at the current time.
The only way to fix the issue is to get 201 over the line soon or a deal for CLX or another deal in the next year with cash payments and higher share price plus some decent lab contracts.
No board changes can divert away from that fact and change the situation. It needs experience and knowledge of this industry.
Buying at 54p when the share price is now less than 4p would be considered by mny to be a 'bust approach'. A lesson to all might be to ignore what most post on these boards especially when they post with a "Strong Buy' opinion.
PM2022
Posted in: VAL
Posts: 2,793
Price: 54.25
Strong Buy
RE: 90 Mins to go...Tick..Tock..tick26 Oct 2021 16:12
This should a lesson for all. Do your homework and know what lies ahead. Don't listen to the children here who have not done the homework and don't be shaken by MM games. I was not nervous at all by the drop and added more.
Should you need a reminder listen to the recent interviews by Suzy where it is confirmed a deal is highly likely before year end but that was a few weeks ago and a deal should be arriving soon. Given our current market cap we are very cheap and a possibly multi-bagger here.